Thus, the in vivo efficacy of recombinant survivin as a cancer vaccine was tested along with the adjuvants alum and Mw in the breast cancer model 4T1, which expresses high levels of survivin compared to normal breast tissue (149). This evidence concerns the gene BIRC5 and breast cancer.